Geftinat

✅ Treats non-small lung cancer
✅ Inhibits cancer cell growth
✅ Effective targeted therapy
✅ Oral administration convenience
✅ Reduces tumor size

This product is currently out of stock and unavailable.

Geftinatmg Tablet is prescribed for treating non-small cell lung cancer in patients where the cancer has metastasized (spread to other body parts), who possess abnormal epidermal growth factor receptor (EGFR) genes, and haven’t undergone prior cancer treatment.

This medication can be taken with or without meals, though maintaining a consistent daily schedule enhances effectiveness. Continue treatment as directed by your physician. Treatment duration depends on individual response and medical requirements. Strict adherence to your doctor’s instructions is crucial, as improper use or overdose may lead to severe adverse effects. While benefits may take weeks or months to manifest, do not discontinue use without medical advice.

Common side effects include nausea, skin rashes, vomiting, and weight reduction. Severe diarrhea may occur – maintain hydration or consult your doctor if persistent. This medication increases photosensitivity; wear protective clothing or sunscreen when outdoors. Report any mouth ulcers, vision changes, or breathing difficulties to your healthcare provider immediately. Regular liver function tests may be required during treatment.

Inform your medical team about all concurrent medications due to potential interactions. This drug is contraindicated during pregnancy and breastfeeding. Both male and female patients must use effective contraception throughout treatment. When taking antacids or other medications, maintain at least a 2-hour interval after this cancer medication.

THERAPEUTIC APPLICATIONS OF GEFTINAT TABLET

  • Management of non-small cell lung carcinoma

THERAPEUTIC ADVANTAGES OF GEFTINAT TABLET

For Non-small Cell Lung Cancer

As a predominant form of lung malignancy affecting both smokers and non-smokers, non-small cell lung cancer responds to Geftinatmg Tablet therapy, which may be administered as monotherapy or combined with other agents. This highly potent medication carries significant toxicity risks – thorough discussion of risk-benefit analysis with your oncologist is essential. Maintain alcohol abstinence during treatment and ensure adequate hydration.

ADVERSE EFFECTS OF GEFTINAT TABLET

Most adverse reactions are transient and resolve as your system adapts to the medication. Persistent symptoms or concerns warrant medical consultation.

Frequently observed reactions to Geftinat

  • Gastrointestinal disturbances (diarrhea)
  • Dermal dryness
  • Reduced appetite
  • Nausea
  • Cutaneous eruptions
  • Oral inflammation (stomatitis)
  • Emesis
  • Generalized fatigue
  • Body mass reduction

ADMINISTRATION GUIDELINES

Ingest this medication whole as prescribed – do not crush, chew, or break the tablet. While food doesn’t affect absorption, maintaining regular dosing times optimizes therapeutic outcomes.

PHARMACOLOGICAL MECHANISM

As an antineoplastic agent, Geftinatmg Tablet inhibits the activity of aberrant proteins that stimulate cancerous cell proliferation, thereby retarding or arresting cancer progression.

Important Notice:

This information aims to provide accurate, expert-reviewed content for educational purposes. It does not substitute professional medical advice, diagnosis, or treatment. The content may not encompass all potential adverse effects, contraindications, or drug interactions. Always consult your healthcare provider regarding medical conditions or treatments. This information supports but does not replace the essential physician-patient relationship.

Strength

250 mg

Quantity

30 Tablet/s, 60 Tablet/s, 90 Tablet/s

Pharma Form

Tablet/s

Manufacturer

Cipla Inc

Treatment

Non-small cell lung cancer

Generic Brand

Bicalutamide

Reviews

There are no reviews yet

Add a review
Geftinat Geftinat
Rating*
0/5
* Rating is required
* Answer is required
Your review
* Review is required
Name
* Name is required
Add photos or video to your review
* Please confirm that you are not a robot